M
11.96
-0.18 (-1.48%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Maze Therapeutics, Inc. | 看跌 | - |
AIStockmoo 评分
0.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.75 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 11.49% |
| 机构持股比例 | 56.93% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 30.00 (JP Morgan, 150.84%) | 购买 |
| 中 | 28.00 (134.11%) | |
| 低 | 19.00 (Guggenheim, 58.86%) | 购买 |
| 平均值 | 25.67 (114.63%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 10.41 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 19.00 (58.86%) | 购买 | 10.09 |
| 25 Feb 2025 | 19.00 (58.86%) | 购买 | 10.57 | |
| JP Morgan | 25 Feb 2025 | 30.00 (150.84%) | 购买 | 10.57 |
| Leerink Partners | 25 Feb 2025 | 28.00 (134.11%) | 购买 | 10.57 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合